Annual Total Expenses
$765.00 K
-$115.00 K-13.07%
31 December 2023
Summary:
XTL Biopharmaceuticals annual total expenses is currently $765.00 thousand, with the most recent change of -$115.00 thousand (-13.07%) on 31 December 2023. During the last 3 years, it has fallen by -$183.00 thousand (-19.30%). XTLB annual total expenses is now -97.13% below its all-time high of $26.64 million, reached on 31 December 2007.XTLB Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Expenses
$175.00 K
-$25.00 K-12.50%
31 March 2024
Summary:
XTL Biopharmaceuticals quarterly total expenses is currently $175.00 thousand, with the most recent change of -$25.00 thousand (-12.50%) on 31 March 2024. Over the past year, it has increased by +$24.00 thousand (+15.89%). XTLB quarterly total expenses is now -97.73% below its all-time high of $7.72 million, reached on 30 June 2007.XTLB Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
XTLB Total Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -13.1% | +15.9% |
| 3 y3 years | -19.3% | -16.7% |
| 5 y5 years | -3.5% | -12.1% |
XTLB Total Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -25.8% | at low | -38.8% | +15.9% |
| 5 y | 5 years | -25.8% | at low | -63.1% | +15.9% |
| alltime | all time | -97.1% | +129.8% | -97.7% | +103.4% |
XTL Biopharmaceuticals Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2024 | - | $175.00 K(-12.5%) |
| Dec 2023 | $765.00 K(-13.1%) | $200.00 K(+32.5%) |
| Sept 2023 | - | $151.00 K(-7.4%) |
| June 2023 | - | $163.00 K(-35.1%) |
| Mar 2023 | - | $251.00 K(+11.6%) |
| Dec 2022 | $880.00 K(-14.6%) | $225.00 K(+10.3%) |
| Sept 2022 | - | $204.00 K(+1.0%) |
| June 2022 | - | $202.00 K(-18.9%) |
| Mar 2022 | - | $249.00 K(-12.9%) |
| Dec 2021 | $1.03 M(+8.8%) | $286.00 K(+36.2%) |
| Sept 2021 | - | $210.00 K(-30.7%) |
| June 2021 | - | $303.00 K(+30.6%) |
| Mar 2021 | - | $232.00 K(-9.7%) |
| Dec 2020 | $948.00 K(+12.6%) | $257.00 K(-45.8%) |
| Sept 2020 | - | $474.00 K(0.0%) |
| June 2020 | - | $474.00 K(+84.4%) |
| Mar 2020 | - | $257.00 K(+5.3%) |
| Dec 2019 | $842.00 K(+6.2%) | $244.00 K(+22.6%) |
| Sept 2019 | - | $199.00 K(-0.5%) |
| June 2019 | - | $200.00 K(+0.5%) |
| Mar 2019 | - | $199.00 K(-10.0%) |
| Dec 2018 | $793.00 K(-36.4%) | $221.00 K(+16.3%) |
| Sept 2018 | - | $190.00 K(+3.3%) |
| June 2018 | - | $184.00 K(-7.1%) |
| Mar 2018 | - | $198.00 K(-30.8%) |
| Dec 2017 | $1.25 M(-27.3%) | $286.00 K(+50.5%) |
| Sept 2017 | - | $190.00 K(-57.1%) |
| June 2017 | - | $443.00 K(+35.5%) |
| Mar 2017 | - | $327.00 K(-5.2%) |
| Dec 2016 | $1.71 M(-14.6%) | $345.00 K(+15.0%) |
| Sept 2016 | - | $300.00 K(-35.6%) |
| June 2016 | - | $466.00 K(-22.6%) |
| Mar 2016 | - | $602.00 K(-20.2%) |
| Dec 2015 | $2.01 M(-0.7%) | $754.00 K(+90.4%) |
| Sept 2015 | - | $396.00 K(-17.7%) |
| June 2015 | - | $481.00 K(+27.9%) |
| Mar 2015 | - | $376.00 K(-42.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2014 | $2.02 M(+43.3%) | $658.00 K(+79.3%) |
| Sept 2014 | - | $367.00 K(-8.9%) |
| June 2014 | - | $403.00 K(-32.2%) |
| Mar 2014 | - | $594.00 K(-144.3%) |
| Dec 2013 | $1.41 M(-44.1%) | -$1.34 M(+276.7%) |
| Sept 2013 | - | -$356.00 K(-123.5%) |
| June 2013 | - | $1.51 M(-5.3%) |
| Mar 2013 | - | $1.60 M(+59.6%) |
| Dec 2012 | $2.53 M(+106.9%) | $1.00 M(+96.9%) |
| Sept 2012 | - | $508.00 K(-17.7%) |
| June 2012 | - | $617.00 K(+53.9%) |
| Mar 2012 | - | $401.00 K(+19.7%) |
| Dec 2011 | $1.22 M(-2.8%) | $335.00 K(+15.9%) |
| Sept 2011 | - | $289.00 K(+2.1%) |
| June 2011 | - | $283.00 K(-15.3%) |
| Mar 2011 | - | $334.00 K(+8.4%) |
| Dec 2010 | $1.26 M(-148.9%) | $308.00 K(+4.1%) |
| Sept 2010 | - | $296.00 K(-6.6%) |
| June 2010 | - | $317.00 K(-5.4%) |
| Mar 2010 | - | $335.00 K(-106.5%) |
| Dec 2009 | -$2.57 M(-114.9%) | -$5.15 M(-1980.7%) |
| Sept 2009 | - | $274.00 K(-77.4%) |
| June 2009 | - | $1.21 M(-26.3%) |
| Mar 2009 | - | $1.65 M(+146.4%) |
| Dec 2008 | $17.21 M(-35.4%) | $668.00 K(-80.1%) |
| Sept 2008 | - | $3.36 M(-40.0%) |
| June 2008 | - | $5.60 M(-27.5%) |
| Dec 2007 | $26.64 M(+61.5%) | - |
| June 2007 | - | $7.72 M(+99.6%) |
| Dec 2006 | $16.50 M(+4.5%) | - |
| June 2006 | - | $3.87 M(+0.3%) |
| Dec 2005 | $15.79 M(-21.9%) | - |
| June 2005 | - | $3.86 M(-28.7%) |
| Dec 2004 | $20.23 M(+38.9%) | - |
| June 2004 | - | $5.41 M |
| Dec 2003 | $14.56 M(-17.8%) | - |
| Dec 2002 | $17.71 M(+17.1%) | - |
| Dec 2001 | $15.12 M | - |
FAQ
- What is XTL Biopharmaceuticals annual total expenses?
- What is the all time high annual total expenses for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals annual total expenses year-on-year change?
- What is XTL Biopharmaceuticals quarterly total expenses?
- What is the all time high quarterly total expenses for XTL Biopharmaceuticals?
- What is XTL Biopharmaceuticals quarterly total expenses year-on-year change?
What is XTL Biopharmaceuticals annual total expenses?
The current annual total expenses of XTLB is $765.00 K
What is the all time high annual total expenses for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high annual total expenses is $26.64 M
What is XTL Biopharmaceuticals annual total expenses year-on-year change?
Over the past year, XTLB annual total expenses has changed by -$115.00 K (-13.07%)
What is XTL Biopharmaceuticals quarterly total expenses?
The current quarterly total expenses of XTLB is $175.00 K
What is the all time high quarterly total expenses for XTL Biopharmaceuticals?
XTL Biopharmaceuticals all-time high quarterly total expenses is $7.72 M
What is XTL Biopharmaceuticals quarterly total expenses year-on-year change?
Over the past year, XTLB quarterly total expenses has changed by +$24.00 K (+15.89%)